Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy
Q Zhang, J Zhao, T Xu - Fundamental & Clinical Pharmacology, 2023 - Wiley Online Library
Glioblastoma is characterized by extensive vascularization and is highly resistant to current
therapy. Identification of drugs that target tumor directly and angiogenesis processes present …
therapy. Identification of drugs that target tumor directly and angiogenesis processes present …
Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy
Q Zhang, J Zhao, T Xu - Fundamental & clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Glioblastoma is characterized by extensive vascularization and is highly resistant to current
therapy. Identification of drugs that target tumor directly and angiogenesis processes present …
therapy. Identification of drugs that target tumor directly and angiogenesis processes present …
Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth and survival of glioblastoma and enhances chemotherapy's efficacy.
Q Zhang, J Zhao, T Xu - Fundamental & Clinical Pharmacology, 2023 - europepmc.org
Glioblastoma is characterized by extensive vascularization and is highly resistant to current
therapy. Identification of drugs that target tumor directly and angiogenesis processes present …
therapy. Identification of drugs that target tumor directly and angiogenesis processes present …